Active	Status	Sponsor type	Region	Phase	Filter
6 Active 4 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Camidge, Ross D
RAMP-202, NCT04620330 / 2020-004265-39: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer Trial initiated for LGSOC and KRAS mutated NSCLC Dec 2020 - Dec 2020: Trial initiated for LGSOC and KRAS mutated NSCLC	Completed	2	90	Europe, US	avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063	Verastem, Inc.	Non Small Cell Lung Cancer, KRAS Activating Mutation	08/23	12/23
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement	Recruiting	1/2	359	Europe, Canada, Japan, US, RoW	NVL-520	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	10/25	10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation	Recruiting	1/2	470	Europe, Canada, Japan, US, RoW	NVL-655	Nuvalent Inc., Nuvalent, Inc.	Locally Advanced Solid Tumor, Metastatic Solid Tumor	02/26	03/26
NCT05845671: Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations	Recruiting	1/2	12	US	Amivantamab 1050mg, JNJ-61186372, Amivantamab 1400mg, Amivantamab (to be determined)	University of Colorado, Denver, Janssen Research & Development, LLC	Lung Cancer, Non Small Cell Lung Cancer	01/27	01/28
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors Jan 2023 - Dec 2023: Approval in US for 2L NSCLC Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial NMPA granted in patients with for the treatment of patients with ROS1-positive NSCLC Feb 2022 - Feb 2022: NMPA granted in patients with for the treatment of patients with ROS1-positive NSCLC Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021 Oct 2021 - Oct 2021: Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021 Granted in patients with NTRK-positive, TKI-pretreated advanced solid tumors Oct 2021 - Oct 2021: Granted in patients with NTRK-positive, TKI-pretreated advanced solid tumors Granted for ROS1-positive advanced NSCLC Aug 2021 - Aug 2021: Granted for ROS1-positive advanced NSCLC For TKI-naive ROS1-positive NSCLC from TRIDENT-1 study Jan 2021 - Jan 2021: For TKI-naive ROS1-positive NSCLC from TRIDENT-1 study For ROS1+ve metastatic NSCLC based on TRIDENT-1 study Dec 2020 - Dec 2020: For ROS1+ve metastatic NSCLC based on TRIDENT-1 study For 2L treatment of patients with advanced solid tumors Aug 2020 - Aug 2020: For 2L treatment of patients with advanced solid tumors Interim data from P2 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors Aug 2020 - Aug 2020: Interim data from P2 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors From TRIDENT-1 trial [screenshot] Sep 2019 - Sep 2019: From TRIDENT-1 trial [screenshot] From P1 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors Jun 2019 - Jun 2019: From P1 portion of P1/2 TRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors From P1 portion of P1/2 TRIDENT-1 trial at ASCO 2019 [screenshot] May 2019 - May 2019: From P1 portion of P1/2 TRIDENT-1 trial at ASCO 2019 [screenshot] FromTRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors [screenshot] Sep 2018 - Sep 2018: FromTRIDENT-1 trial for ROS-1 positive NSCLC and NTRK-positive solid tumors [screenshot] Interim data for ROS1 fusion +ve NSCLC Sep 2018 - Sep 2018: Interim data for ROS1 fusion +ve NSCLC From TRIDENT-1 trial in patients with advanced ALK/ROS1/NTRK+ Cancers at ASCO 2018 [screenshot] Jun 2018 - Jun 2018: From TRIDENT-1 trial in patients with advanced ALK/ROS1/NTRK+ Cancers at ASCO 2018 [screenshot] More	Recruiting	1/2	500	Europe, Canada, Japan, US, RoW	Oral repotrectinib (TPX-0005), repotrectinib	Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.	Locally Advanced Solid Tumors, Metastatic Solid Tumors	02/28	02/28
Camidge, David Ross
No trials found
Silveira, Roberta Kay
No trials found